<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795210</url>
  </required_header>
  <id_info>
    <org_study_id>DK63639A</org_study_id>
    <secondary_id>R01DK063639</secondary_id>
    <nct_id>NCT00795210</nct_id>
  </id_info>
  <brief_title>Effects of Short-term Growth Hormone in HIV-infected Patients</brief_title>
  <official_title>Effects of Short-term Growth Hormone in HIV-infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the short-term effects of two different doses of
      growth hormone, compared to treatment with growth hormone releasing hormone, on the brain's
      secretion of growth hormone and the body's glucose metabolism. We hypothesize that growth
      hormone administration will alter the body's endogenous pulsatile growth hormone secretion
      and that higher dose growth hormone may decrease insulin sensitivity. We hypothesize that
      growth hormone releasing hormone will augment endogenous GH pulsatility and be neutral to
      insulin sensitivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine the differential effects of growth
      hormone releasing hormone (GHRH) vs. low dose physiologic growth hormone (GH) vs. higher dose
      GH treatment and withdrawal on endogenous overnight growth hormone secretion and pulsatility,
      as well as insulin-stimulated glucose uptake. Subjects with HIV-infection will be randomized
      to receive one of three treatments: GHRH 2mg/day, or growth hormone 6mcg/kg/day (physiologic
      &quot;low&quot; dose), or growth hormone 2mg/day (&quot;higher&quot; dose) for 2 weeks. At baseline and after two
      weeks of treatment, we will assess overnight growth hormone by frequent sampling as well as
      insulin stimulated glucose uptake by clamp. Subjects will then stop the treatment and will
      return for an identical assessment after a 2 week withdrawal period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug</measure>
    <time_frame>after 2 weeks treatment</time_frame>
    <description>Serum was sampled for growth hormone concentrations every 20 minutes between 20:00 (8pm) and 07:40 (7:40am). Subjects in GH 6mcg/kg/day and GH 2mg daily groups received their final dose of study drug approximately 36 hours prior to start of sampling. Subjects in Growth Hormone Releasing Hormone group received their final dose of study drug approximately 8 hours prior to start of sampling.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>after two weeks treatment</time_frame>
    <description>insulin-stimulated glucose uptake as measured by euglycemic hyperinsulinemic clamp; &quot;M&quot; value (infusion rate with space correction, using method of DeFronzo) for the steady state between 100-120 minutes of clamp is given</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>HIV Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>GH 6mcg/kg/d</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human growth hormone 6mcg/kg SC once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GH 2mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant human growth hormone 2mg SC once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Growth Hormone Releasing Hormone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth hormone</intervention_name>
    <description>Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks</description>
    <arm_group_label>GH 6mcg/kg/d</arm_group_label>
    <arm_group_label>GH 2mg daily</arm_group_label>
    <other_name>rhGH from Teva Pharmaceuticals</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone Releasing Hormone</intervention_name>
    <description>Tesamorelin (GHRH) 2mg SC QD x 2 weeks</description>
    <arm_group_label>Growth Hormone Releasing Hormone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  previously diagnosed HIV infection

          -  Stable antiretroviral regimen for at least 12 weeks prior to enrollment

          -  Waist circumference &gt;/= 95cm and waist-to-hip ratio &gt;/= 0.94 for males or waist
             circumference &gt;/=94cm and WHR &gt;/= 0.88 for females, occurring in the context of
             treatment for HIV disease

          -  Subjective evidence of at least one of the following changes, occurring during the
             treatment of HIV disease: increased abdominal girth, relative loss of fat in the
             extremities, or relative loss of fat in the face

        Exclusion Criteria:

          -  Use of anti-diabetic agents, Megace, testosterone, or any steroid use within 6 months
             of the study

          -  Use of GH or Growth hormone releasing factor within six months of starting the study

          -  Change in lipid lowering or antihypertensive regimen within 3 months of screening

          -  Fasting blood sugar &gt;126mg/dL, SGOT &gt; 2.5 times ULN, Hgb &lt; 12.0 g/dL, creatinine &gt; 1.4
             mg/dL, FSH &gt; 20 IU/L in women, or CD4 count &lt; 200

          -  Carpal tunnel syndrome

          -  Severe chronic illness or active malignancy or history of pituitary malignancy or
             history of colon cancer

          -  For men, history of prostate cancer or evidence of prostate malignancy by PSA &gt; 5ng/mL

          -  Prior history of hypopituitarism, head irradiation, or any other condition known to
             affect the GH axis

          -  positive beta-HCG (women only)

          -  Oral contraceptives, depo provera, or combined progesterone-estrogen injections,
             transdermal contraceptive patches, estrogen or progestin coated IUD's within 6 months
             of the study

          -  weight &lt; 110 pounds
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven K Grinspoon, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MGH</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <results_first_submitted>October 9, 2013</results_first_submitted>
  <results_first_submitted_qc>December 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 8, 2014</results_first_posted>
  <last_update_submitted>December 6, 2013</last_update_submitted>
  <last_update_submitted_qc>December 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Steven K. Grinspoon, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV lipodystrophy</keyword>
  <keyword>growth hormone</keyword>
  <keyword>growth hormone releasing hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Growth Hormone-Releasing Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred between January, 2009 and November, 2012, in the Boston area.</recruitment_details>
      <pre_assignment_details>Once patients were found to be eligible (after screen visit) and agreed to participate, there were no additional events prior to baseline.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>GH 6mcg/kg/d</title>
          <description>Recombinant human growth hormone 6mcg/kg SC once daily</description>
        </group>
        <group group_id="P2">
          <title>GH 2mg Daily</title>
          <description>Recombinant human growth hormone 2mg SC once daily</description>
        </group>
        <group group_id="P3">
          <title>Growth Hormone Releasing Hormone</title>
          <description>Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GH 6mcg/kg/d</title>
          <description>Recombinant human growth hormone 6mcg/kg SC once daily</description>
        </group>
        <group group_id="B2">
          <title>GH 2mg Daily</title>
          <description>Recombinant human growth hormone 2mg SC once daily</description>
        </group>
        <group group_id="B3">
          <title>Growth Hormone Releasing Hormone</title>
          <description>Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="7"/>
                    <measurement group_id="B2" value="49" spread="6"/>
                    <measurement group_id="B3" value="47" spread="4"/>
                    <measurement group_id="B4" value="48" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug</title>
        <description>Serum was sampled for growth hormone concentrations every 20 minutes between 20:00 (8pm) and 07:40 (7:40am). Subjects in GH 6mcg/kg/day and GH 2mg daily groups received their final dose of study drug approximately 36 hours prior to start of sampling. Subjects in Growth Hormone Releasing Hormone group received their final dose of study drug approximately 8 hours prior to start of sampling.</description>
        <time_frame>after 2 weeks treatment</time_frame>
        <population>Overnight GH data were unavailable for 1 subject in the GH 6mcg/kg group and thus are not included in analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GH 6mcg/kg/d</title>
            <description>Recombinant human growth hormone 6mcg/kg SC once daily</description>
          </group>
          <group group_id="O2">
            <title>GH 2mg Daily</title>
            <description>Recombinant human growth hormone 2mg SC once daily</description>
          </group>
          <group group_id="O3">
            <title>Growth Hormone Releasing Hormone</title>
            <description>Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug</title>
          <description>Serum was sampled for growth hormone concentrations every 20 minutes between 20:00 (8pm) and 07:40 (7:40am). Subjects in GH 6mcg/kg/day and GH 2mg daily groups received their final dose of study drug approximately 36 hours prior to start of sampling. Subjects in Growth Hormone Releasing Hormone group received their final dose of study drug approximately 8 hours prior to start of sampling.</description>
          <population>Overnight GH data were unavailable for 1 subject in the GH 6mcg/kg group and thus are not included in analysis.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.23" lower_limit="0.08" upper_limit="0.68"/>
                    <measurement group_id="O2" value="0.07" lower_limit="0.04" upper_limit="0.12"/>
                    <measurement group_id="O3" value="1.24" lower_limit="0.76" upper_limit="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Kruskal-Wallis Test for overall difference between groups</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Sensitivity</title>
        <description>insulin-stimulated glucose uptake as measured by euglycemic hyperinsulinemic clamp; &quot;M&quot; value (infusion rate with space correction, using method of DeFronzo) for the steady state between 100-120 minutes of clamp is given</description>
        <time_frame>after two weeks treatment</time_frame>
        <population>Insulin stimulated glucose uptake data were unavailable for 4 subjects in the GH 2mg group. Two subjects did not have sufficient IV access and thus could not complete the clamp procedure. Two subjects did not reach target glucose and thus their data could not be used.</population>
        <group_list>
          <group group_id="O1">
            <title>GH 6mcg/kg/d</title>
            <description>Recombinant human growth hormone 6mcg/kg SC once daily</description>
          </group>
          <group group_id="O2">
            <title>GH 2mg Daily</title>
            <description>Recombinant human growth hormone 2mg SC once daily</description>
          </group>
          <group group_id="O3">
            <title>Growth Hormone Releasing Hormone</title>
            <description>Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity</title>
          <description>insulin-stimulated glucose uptake as measured by euglycemic hyperinsulinemic clamp; &quot;M&quot; value (infusion rate with space correction, using method of DeFronzo) for the steady state between 100-120 minutes of clamp is given</description>
          <population>Insulin stimulated glucose uptake data were unavailable for 4 subjects in the GH 2mg group. Two subjects did not have sufficient IV access and thus could not complete the clamp procedure. Two subjects did not reach target glucose and thus their data could not be used.</population>
          <units>mg/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="2.9"/>
                    <measurement group_id="O2" value="7.5" spread="3.2"/>
                    <measurement group_id="O3" value="9.9" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AE data were actively collected during the 4 weeks of the study period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GH 6mcg/kg/d</title>
          <description>Recombinant human growth hormone 6mcg/kg SC once daily</description>
        </group>
        <group group_id="E2">
          <title>GH 2mg Daily</title>
          <description>Recombinant human growth hormone 2mg SC once daily</description>
        </group>
        <group group_id="E3">
          <title>Growth Hormone Releasing Hormone</title>
          <description>Growth Hormone Releasing Hormone (Tesamorelin) 2mg daily, injected subcutaneously, x 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema/Extremity Swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <description>elevated fasting blood sugar</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>injection site bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was completed early due to the lack of availability of study drug for one of the arms.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven Grinspoon, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-9109</phone>
      <email>sgrinspoon@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

